VASCULAR BIOGENICS LTD (VBLT) Forecast, Price Target & Analyst Ratings

NASDAQ:VBLT • IL0011327454

Current stock price

0.156 USD
-0.02 (-8.77%)
At close:
0.168 USD
+0.01 (+7.69%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VASCULAR BIOGENICS LTD (VBLT).

Forecast Snapshot

Consensus Price Target

Price Target
$5.10
+ 3,169.23% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Nov 13, 2023
Period
Q3 / 2023
EPS Estimate
-$0.15
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
45.71%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.10
Upside
+ 3,169.23%
From current price of $0.16 to mean target of $5.10, Based on 7 analyst forecasts
Low
$5.05
Median
$5.10
High
$5.25

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for VBLT. The average price target is 5.1 USD. This implies a price increase of 3169.23% is expected in the next year compared to the current price of 0.156.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

VBLT Current Analyst RatingVBLT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

VBLT Historical Analyst RatingsVBLT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
45.71%
VBLT was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about VBLT.
In the previous month the buy percentage consensus was at a similar level.
VBLT was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-07-21Chardan CapitalDowngrade Buy -> Neutral
2022-07-20HC Wainwright & Co.Downgrade Buy -> Neutral
2022-04-28Chardan CapitalInitiate Buy
2021-06-03Roth CapitalMaintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Nov 13, 2023
Period
Q3 / 2023
EPS Estimate
-$0.15
Revenue Estimate
N/A
Revenue Q2Q
N/A
EPS Q2Q
-27.50%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

VBLT is expected to report earnings on 11/13/2023. The consensus EPS estimate for the next earnings is -0.15 USD and the consensus revenue estimate is null USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
VBLT revenue by date.VBLT revenue by date.
920K
64.29%		768K
-16.52%		658K
-14.32%		1.962M
198.18%		1.962MN/AN/AN/AN/AN/AN/A
EBITDA
YoY % growth
VBLT ebitda by date.VBLT ebitda by date.
-23.29M
-23.49%		-28.74M
-23.40%		-31.795M
-10.63%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
VBLT ebit by date.VBLT ebit by date.
-24.48M
-21.91%		-29.996M
-22.53%		-32.853M
-9.52%		-11.69M
64.42%		-18.278M
-56.36%		-31.73M
-73.59%		-76.493M
-141.07%		-80.313M
-4.99%		-84.655M
-5.41%		-88.796M
-4.89%		-92.479M
-4.15%
Operating Margin
VBLT operating margin by date.VBLT operating margin by date.
-2,660.87%-3,905.73%-4,992.86%-595.83%-931.62%N/AN/AN/AN/AN/AN/A
EPS
YoY % growth
VBLT eps by date.VBLT eps by date.
-0.56
-1.82%		-0.45
19.64%		N/A
-17.87%		-0.61
-15.38%		-0.75
-23.33%		-0.83
-9.46%		-0.88
-6.17%		-0.93
-5.81%		-0.99
-6.59%		-1.05
-6.19%		-1.10
-4.85%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.15
-27.50%		-0.16
-14.29%
Revenue
Q2Q % growth		N/AN/A
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		N/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

VBLT Yearly Revenue VS EstimatesVBLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VBLT Yearly EPS VS EstimatesVBLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-15.92%
EPS Next 5 Year
-11.84%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

VASCULAR BIOGENICS LTD / VBLT Forecast FAQ

What do analysts expect the price target to be for VASCULAR BIOGENICS LTD (VBLT)?

7 analysts have analysed VBLT and the average price target is 5.1 USD. This implies a price increase of 3169.23% is expected in the next year compared to the current price of 0.156.

Can you provide the upcoming earnings date for VASCULAR BIOGENICS LTD?

VASCULAR BIOGENICS LTD (VBLT) will report earnings on 2023-11-13, before the market open.

How do analysts rate VASCULAR BIOGENICS LTD (VBLT)?

The consensus rating for VASCULAR BIOGENICS LTD (VBLT) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.